ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.
Wu
J
J
Meng
F
F
Ying
Y
Y
Peng
Z
Z
Daniels
L
L
Bornmann
W G
WG
Quintás-Cardama
A
A
Roulston
D
D
Talpaz
M
M
Peterson
L F
LF
Donato
N J
NJ
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001549:Benzamides; D001555:Benzene Derivatives / Q000494:pharmacology*; D002478:Cells, Cultured; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D007377:Interleukin-3 / Q000494:pharmacology; D020014:K562 Cells; D051379:Mice; D009154:Mutation / Q000235:genetics; D010766:Phosphorylation / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology*; D054448:Precursor Cells, B-Lymphoid / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology; D014443:Tyrosine / Q000378:metabolism
D000970:Antineoplastic Agents; D001549:Benzamides; D001555:Benzene Derivatives; D007377:Interleukin-3; C499758:ON012380; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D014443:Tyrosine; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib